John Oyler, Chief Executive Officer at BeOne Medicines Ltd. (ONC), sold 240,810 shares at $350.00 ($86.5M) on 2026-08-10, disclosed to the SEC on 2026-08-12.
Scheduled sale ($86.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $350.00 | 67 | $23K | 0.0% |
| 2 | $351.80 | 2,813 | $990K | 1.1% |
| 3 | $353.32 | 3,673 | $1.3M | 1.5% |
| 4 | $354.78 | 6,717 | $2.4M | 2.8% |
| 5 | $355.66 | 3,476 | $1.2M | 1.4% |
| 6 | $356.62 | 12,418 |
| $4.4M |
| 5.1% |
| 7 | $357.67 | 15,869 | $5.7M | 6.6% |
| 8 | $358.70 | 45,044 | $16.2M | 18.7% |
| 9 | $359.50 | 21,254 | $7.6M | 8.8% |
| 10 | $360.63 | 3,680 | $1.3M | 1.5% |
| 11 | $359.32 | 13,695 | $4.9M | 5.7% |
| 12 | $360.33 | 8,081 | $2.9M | 3.4% |
| 13 | $361.47 | 14,569 | $5.3M | 6.1% |
| 14 | $362.34 | 11,568 | $4.2M | 4.8% |
| 15 | $363.45 | 13,403 | $4.9M | 5.6% |
| 16 | $364.31 | 5,211 | $1.9M | 2.2% |
| 17 | $365.26 | 3,176 | $1.2M | 1.3% |
| 18 | $366.31 | 1,200 | $440K | 0.5% |
| 19 | $367.00 | 4 | $1K | 0.0% |
| 20 | $354.71 | 1,980 | $702K | 0.8% |
| 21 | $356.43 | 2,515 | $896K | 1.0% |
| 22 | $357.63 | 15,396 | $5.5M | 6.4% |
| 23 | $358.41 | 20,899 | $7.5M | 8.7% |
| 24 | $359.12 | 14,102 | $5.1M | 5.9% |
| Total | $359.12 avg | 240,810 | $86.5M | 100% |
| Filing → |
| ONC | SELL | 2026-07-17 | $20.2M | — | Filing → |
| ONC | SELL | 2026-07-14 | $18.3M | — | Filing → |
| ONC | SELL | 2026-07-14 | $44.6M | — | Filing → |